Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 KSI-301 versus aflibercept in treatment-naive diabetic macular edema
ChiCTR2100053500Phase 3Not yet recruiting
- Sponsor
- Kodiak Sciences
- Start
- Mar 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tarcocimab tedromer and aflibercept in diabetic macular edema (DME) (2 arms), sponsored by Kodiak Sciences. Primary endpoint: Change in best corrected visual acuity. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
tarcocimab tedromeraflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2100053500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053500.